

First schedule1-10 μ g HBcAg / acemannan 3mg/mL


IN

2-10 μ g HBcAg / PBS 1X

IN


3-10 μ g HBcAg / alum 0.5mg/mL

SC

**Fig. 1**


Second Schedule

1-10 μ g HBsAg/ PBS 1X	IN
2-10 μ g HBsAg/ acemannan 3mg/mL	IN
3-10 μ g HBsAg/ 10 μ g HBcAg / PBS 1X	IN
4-10 μ g HBsAg/ Alum 0.5mg/mL	SC

**Fig. 2**

Third schedul

1- 5 μ g HBsAg / PBS 1X	IN
2- 5 μ g HBsAg / 5 μ g HBcAg	IN
3- 5 μ g HBsAg / 10 μ g HBcAg	IN
4- 5 μ g HBsAg / 20 μ g HBcAg	IN
5- 5 μ g HBsAg / acemannan 3mg/mL	IN
6- 5 μ g HBsAg / alum 0.5mg/mL	IM

**Fig. 3**

Fourth Schedule: Synergism at mucosal lev 1.

Acemannan 3mg/mL	X			X		X		
HBcAg 5µg/dose		X			X		X	
HBsAg 5µg/dose	X	X	X			X	X	
VLP /HPV 5µg/dose	X	X	X	X	X			X






Fig. 4 Composition, per groups, in the upper part of the figure.

T04T60" 20425860

Fifth Schedule1-10 μ g HCV NC/ PBS 1X


IN

2-5 μ g HBsAg/ PBS 1X

IN

3-10 μ g HBsAg/ 10 μ g HCV NC / PBS 1X

IN

**Fig. 5**